The Connected Smart Drug Delivery Systems Market Size is valued at USD 1,443.7 Million in 2023 and is predicted to reach USD 16,465.95 Million by the year 2031 at a 35.62% CAGR during the forecast period for 2024-2031.
Connected Smart Drug Delivery Systems are the devices which perform multiple functions with the highest degree of smartness. Smart drug delivery devices help to reduce the dosage, frequency of the dosage and adverse effects of the drug. These devices are beneficial in the treatment of respiratory diseases, diabetes and other cardiovascular disorders. Connected smart drug delivery systems are more effective and can be self-managed. COVID-19 Pandemic is significantly augmenting the need for such smart (contactless) devices, and hence, in future, there will be a high requirement for such systems, which will ultimately result in Connected Smart Drug Delivery System’s market growth.
Connected smart drug delivery is an attractive industry option with multiple growth opportunities in research and development, technologies, applications, and formulations. Market analysis in terms of the product clearly suggests that the connected sensors segment dominated the market. And the COVID-19 Pandemic is also fueling new developments in the respiratory sector (inhalation devices). Also, recently a Rutgers-led team has created a smart drug delivery system that reduces inflammation in damaged nervous tissues and may help treat spinal cord injuries and other neurological disorders.
Spreading awareness regarding the benefits of connected smart systems over conventional systems is expected to enhance the product demand. Fast adoption of new technologies and smart devices, the invention of new products according to patients’ requirements, and the creation of smartphone applications and low-cost connectivity devices will also help grow this market.
Market Segmentation
The global connected smart drug delivery systems market is segmented on the basis of products, therapeutic area, end user and region. Products market is further categorized into connected inhalers, connected auto injectors, connected needle-free injectors, connected pen injectors, connected insulin pumps, connected wearable injectors/patch pumps, add-on sensors. Based on the different disorders market of therapeutic area can be subdivided into metabolic disorders, neurological disorders, respiratory disorders and others. On the basis of end user, market is sub-divided into hospitals, clinics, and homecare. Based on the region, the market of connected smart drug delivery systems has been segmented into north America, Asia-Pacific, Europe, And LAMEA. Among all, North America is expected to dominate the market during the analysis of forecast period.
Competitive Landscape
Some Of The Key Players In The Connected Smart Drug Delivery Systems Market:
- BIOCORP,
- Elcam Drug Delivery Devices (E3D),
- Novo Nordisk,
- Merck,
- Pneuma Respiratory,
- H&T Presspart,
- Nemera,
- Ypsomed Holdings,
- Unolife Corporation,
- Quio Technologies,
- SHL Group,
- Haselmeier Inc.,
- Portal Instruments Inc,
- West Pharmaceutical Services Inc. ,
- Emperra GmbH E-Health Technologies,
- Amiko Digital Health Limited,
- Cognita Labs,
- DIAMESCO CO., Ltd.,
- Eitan Medical (Q Core Medical Ltd.,
- Avoset Health, Sorrel Medical),
- Enable Injections,
- Bigfoot Biomedical Inc.,
- Medtronic Plc,
- Companion Medical ,
- Sorrel Medical,
- Cohero Health, Inc.,
- Propeller Health,
- Pendiq Intelligent Diabetes Care,
- Phillips-Medisize,
- Becton, Dickinson and Company (BD),
- Noble International Inc,
- etectRx,
- Aterica Inc.,
- Findair Sp. z o. o.,
- Recipharm AB,
- Aero Pump GmbH,
- Jiangsu Delfu medical device Co.,Ltd,
- other prominent players.
The Connected Smart Drug Delivery Systems Market Report Scope
Report Attribute |
Specifications |
Market Size Value In 2023 |
USD 1,443.7 Million |
Revenue Forecast In 2031 |
USD 16,465.95 Million |
Growth Rate CAGR |
CAGR of 35.62% from 2024 to 2031 |
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
Historic Year |
2019 to 2023 |
Forecast Year |
2024-2031 |
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
Segments Covered |
By Product, By Therapeutic Area, By End-User |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
Competitive Landscape |
BIOCORP, Elcam Drug Delivery Devices (E3D), Novo Nordisk, Merck, Pneuma Respiratory, H&T Presspart, Nemera, Ypsomed Holdings, Unolife Corporation, Quio Technologies, SHL Group, Haselmeier Inc., Portal Instruments Inc, West Pharmaceutical Services Inc. , Emperra GmbH E-Health Technologies, Amiko Digital Health Limited, Cognita Labs,DIAMESCO CO., Ltd., Eitan Medical (Q Core Medical Ltd., Avoset Health, Sorrel Medical) , Enable Injections, Bigfoot Biomedical Inc., Medtronic Plc, Companion Medical , Sorrel Medical, Cohero Health, Inc., Propeller Health, Pendiq Intelligent Diabetes Care, Phillips-Medisize, Becton, Dickinson and Company (BD), Noble International Inc, etectRx, Aterica Inc., Findair Sp. z o. o., Recipharm AB, Aero Pump GmbH, Jiangsu Delfu medical device Co.,Ltd, and other prominent players. |
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |